Erschienen in:
01.10.2021 | Microvascular Complications—Retinopathy (R Channa, Section Editor)
Novel Treatments for Diabetic Macular Edema and Proliferative Diabetic Retinopathy
verfasst von:
Nhon T. Le, Zachary A. Kroeger, Weijie Violet Lin, Arshad M. Khanani, Christina Y. Weng
Erschienen in:
Current Diabetes Reports
|
Ausgabe 10/2021
Einloggen, um Zugang zu erhalten
Abstract
Purpose of Review
Diabetic retinopathy (DR), a common cause of vision loss, is projected to increase worldwide, and is associated with significant morbidity. The current standard-of-care treatments can preserve and significantly improve vision in many patients affected by DR. However, challenges such as heavy treatment burden and refractory disease remain. The purpose of this review is to highlight and discuss investigative agents in development for the treatment of DR.
Recent Findings
There are several novel agents with unique mechanisms that may offer greater durability and efficacy compared to existing drugs. Some target new pathways, others leverage a slow-release delivery system, and some modify gene expression through a single-dose treatment.
Summary
While unfavorable adverse events, such as intraocular inflammation, have been observed with longer-durability agents, many investigational products show excellent efficacy and safety profiles. The outcomes of ongoing and future trials may revolutionize the current treatment paradigm for DR.